WHO ICTRP trial
Effect of different dosage of aripiprazole on preventing risperidone-induced…
ChiCTR1900027504 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR1900027504 |
|---|---|
| Public title | Effect of different dosage of aripiprazole on preventing risperidone-induced hyperprolactinemia: a 8-week, multicenter, randomized, open-label, controlled trial |
| Scientific title | Effect of different dosage of aripiprazole on preventing risperidone-induced hyperprolactinemia: a multicenter, randomized, open-label, controlled trial |
| Primary sponsor | Shandong Mental Health Center |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Schizophrenia;F20.901 |
| Interventions | Group A:Patients treated with risperidone alone for 8 weeks;Group B:Patients treated with risperidone and 5 mg/day aripiprazole for 8 weeks;Group C:Patients treated with risperidone and 10 mg/day aripiprazole for 8 weeks |
| Registration date | Nov 17, 2019 |
| Target size | Group A:35;Group B:35;Group C:35 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: